Behind the headlines

Dr David Robert Grimes looks at the eye health issues that are making the news.

Share options

 

NHS to save millions on AMD treatment

A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.

In September, the High Court ruled against the drug giants. 

Login Required

Not yet a member of the College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

OK
Loading...
Loading...
Loading...